Loading stock data…
MannKind Corporation (MNKD)
$4.24+0.10 (+2.42%)
Market ClosedLast close Jun 29
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MannKind Corporation in the Healthcare sector is trading at $4.24 with a market capitalization of $1.2B. Wall Street consensus targets $7.59 (8 analysts), implying a +79.1% move over the next 12 months. The stock is currently 35% below its 52-week high of $6.51, remaining 5.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +79.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $90.17M↓ | $111.95M↑ | $82.13M↑ | $76.53M↓ | $78.35M |
| Gross Profit | $72.70M↓ | $82.28M↑ | $61.93M↑ | $55.96M↓ | $60.84M |
| Operating Income | -$2.98M↑ | -$7.69M↓ | $18.78M↑ | $10.66M↓ | $24.80M |
| Net Income | -$16.62M↓ | -$15.95M↓ | $7.99M↑ | $668,000↓ | $13.16M |
Peer Comparison
JNJUNHPFE
Fundamentals
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
40.40%
Volume
Today's trading volume
3.26M
Recent News
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
Is MNKD a good stock to buy? We came across a bullish thesis on MannKind Corporation on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on MNKD. MannKind Corporation’s share was trading at $3.8400 as of June 24th. MNKD’s trailing and forward P/E were 178.00 and 40.49 respectively according to Yahoo Finance. MannKind […]
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price target on MannKind Corporation (NASDAQ:MNKD) to $11 from $10 and reiterated an Overweight rating. The firm associated this target hike with Afrezza’s approval in pediatric patients, saying that the company’s commercial potential is a “show-me […]
MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data
MannKind (MNKD) is back in focus after presenting a broad package of Afrezza and FUROSCIX data at the American Diabetes Association’s 2026 Scientific Sessions, shortly after securing pediatric FDA approval for Afrezza. See our latest analysis for MannKind. The recent Afrezza pediatric approval and the string of clinical updates around Afrezza, FUROSCIX and nintedanib DPI come after a sharp rebound in MannKind’s 90 day share price return of 35.38%. However, the year to date share price return...
Jim Cramer Says He Blessed MannKind as a Speculation Only
MannKind Corporation (NASDAQ:MNKD) was among the stocks Jim Cramer highlighted on Mad Money as he noted that the market has an appetite for stocks. Answering a caller’s query about the stock during the lightning round, Cramer stated: 100% speculation, a total speculation. In my book, I talk about how you can have one speculation, and […]
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
MannKind Corporation (NASDAQ:MNKD) is one of the most promising penny stocks according to Wall Street analysts. On June 3, MannKind reached key milestones in its clinical program for nintedanib DPI, a dry powder inhalation therapy for idiopathic pulmonary fibrosis/IPF. The company has completed patient randomization for its US Phase 1b INFLO-1 trial and successfully enrolled […]